CD123 CAR-T cell therapy / Chongqing Precision Biotech 
Welcome,         Profile    Billing    Logout  

2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CD123 CAR-T cell therapy / Chongqing Precision Biotech
NCT04265963: CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1/2
45
RoW
CD123 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
12/23
07/24
NCT04272125: Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1/2
40
RoW
CD123 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
12/23
07/24

Download Options